SkinBioTherapeutics plc (LON:SBTX – Get Free Report)’s stock price dropped 1.2% during trading on Tuesday . The stock traded as low as GBX 9 ($0.11) and last traded at GBX 9.14 ($0.11). Approximately 142,806 shares traded hands during trading, a decline of 78% from the average daily volume of 648,659 shares. The stock had previously closed at GBX 9.25 ($0.12).
SkinBioTherapeutics Price Performance
The business has a 50-day simple moving average of GBX 9.35 and a two-hundred day simple moving average of GBX 14.68. The company has a quick ratio of 10.01, a current ratio of 6.57 and a debt-to-equity ratio of 2.66. The stock has a market capitalization of £18.31 million, a price-to-earnings ratio of -457.00 and a beta of 1.61.
SkinBioTherapeutics Company Profile
SkinBioTherapeutics plc, a life science company, engages in identification and development of technology that harnesses the human microbiome to improve health in the United Kingdom, the United States, and Europe. It develops SkinBiotix technology that promotes skin health by harnessing the beneficial properties of probiotic bacteria and the active components; and AxisBiotix technology that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis.
Further Reading
- Five stocks we like better than SkinBioTherapeutics
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- NXP Semiconductors Will Set a New High Soon: $300 in Sight
- How Technical Indicators Can Help You Find Oversold Stocks
- Hilton Demonstrates Asset Light is Right for Investors
- Canada Bond Market Holiday: How to Invest and Trade
- Boston Scientific Bucks the Medtech Slow Down and Raises Outlook
Receive News & Ratings for SkinBioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SkinBioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
